Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HCFA Insulin Pump Coverage Decision Estimates Annual Cost At $3,329

This article was originally published in The Gray Sheet

Executive Summary

The annual cost of insulin therapy administered through a subcutaneous infusion pump is $3,329, the Health Care Financing Administration estimates in a Medicare national coverage decision for the devices in Type I diabetes announced Sept. 24. An effective date will be specified in an upcoming instruction to carriers.

You may also be interested in...



Glucose Monitor Useful In Identifying Asymptomatic Diabetics, MiniMed Says

MiniMed's planned introduction of a consumer version of its continuous home glucose monitor (CGMS) in 2001 is unlikely to result in the phasing-out the professional version introduced in July, given the recent physician debate about what separates a diabetic patient from a "normal" patient.

Glucose Monitor Useful In Identifying Asymptomatic Diabetics, MiniMed Says

MiniMed's planned introduction of a consumer version of its continuous home glucose monitor (CGMS) in 2001 is unlikely to result in the phasing-out the professional version introduced in July, given the recent physician debate about what separates a diabetic patient from a "normal" patient.

Insulin infusion pumps

Estimated annual cost of therapy for Type I diabetes is about $3,330, according to a national coverage decision announced by the Health Care Financing Administration Sept. 24. The agency has yet to make a final payment decision covering the treatment modality, as was incorrectly reported Sept. 27 in "The Gray Sheet" (1p. 12)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel